Erratum to maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients
Erratum to: Transl Pediatr 2023;12:1926-30.
The article (1) entitled “Maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients” (Transl Pediatr 2023;12:1926-30. doi: 10.21037/tp-23-391) unfortunately contained some mistakes in the main text on page 1929. In paragraph 14, the “event-free-survival” should be “overall survival”. The OS should be EFS. The data “91%±4.4% (≤2006) versus 88%±4.3% (>2006)” should be “89%±5.1% (≤2006) versus 87%±4.6% (>2006)”.
The corrected content is presented as below:
Survival analyses revealed that there were no significant differences in overall survival after the reassignment being 89%±5.1% (≤2006) versus 94%±3.2% (>2006). The similar trend was observed for EFS showing 89%±5.1% (≤2006) versus 87%±4.6% (>2006). The small increase in OS observed in the group of patients treated >2006 could be due to the better response of a small subset of patients that relapse.
The authors apologize for these errors and state that these errors do not change the scientific conclusions of the article in any way.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Pérez-García MJ, Segura MF. Maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients. Transl Pediatr 2023;12:1926-30. [Crossref] [PubMed]
